Provided by Tiger Fintech (Singapore) Pte. Ltd.

NovoCure

20.18
+0.92004.78%
Volume:925.40K
Turnover:18.49M
Market Cap:2.22B
PE:-12.90
High:20.50
Open:19.39
Low:19.25
Close:19.26
Loading ...

Company Profile

Company Name:
NovoCure
Exchange:
NASDAQ
Establishment Date:
2000
Employees:
1488
Office Location:
Neuhofstrasse 21,Baar,Zug,Switzerland
Zip Code:
6340
Phone:
- -
Fax:
- -
Introduction:
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Directors

Name
Position
Asaf Danziger
President, Chief Executive Officer and Director
Kinyip Gabriel Leung
Director and Vice Chairman of the Board
William F. Doyle
Director and Executive Chairman
Yoram Palti
Director and Chief Technology Officer
Charles G. Phillips III
Director
Gert Lennart Perlhagen
Director
Louis J. Lavigne, Jr.
Director
Martin J. Madden
Director
William A. Vernon
Director
William Burkoth
Director

Shareholders

Name
Position
Asaf Danziger
President, Chief Executive Officer and Director
Michael J. Ambrogi
Chief Operating Officer
Wilhelmus Groenhuysen
Chief Financial Officer
Eilon Kirson
Chief Science Officer and Head of Research and Development
Todd Longsworth
General Counsel
William F. Doyle
Director and Executive Chairman
Yoram Palti
Director and Chief Technology Officer